Cambridge, UK, August 25, 2016: Owlstone Medical, a diagnostics company, has announced that it has made three appointments to its senior team including business development, clinical research and manufacturing executives. The appointments follow the Company’s recent $7M (£4.9M) investment to commercialize its disease breathalyzer and fund ongoing clinical trials in lung and colon cancer screening.
Chris Hodkinson has been appointed as VP Business Development and takes responsibility for managing the Company’s business development efforts for cancer products. Chris joins Owlstone Medical from Abcodia Ltd, a company developing tests for early detection of cancer, where he was a co-founder, Director and Chief Operating Officer. With over 15 years working in pharma and biotech companies including GSK and Biowisdom, Chris brings extensive commercial, technical and regulatory experience.
Dr Marc van der Schee (MD, PhD) joins the Company as Lead Clinical Research Scientist to design and oversee all clinical trials where he will be responsible for driving product development through into clinical practice. Marc’s 10 years of experience in the field of volatile biomarker research spans medical, epidemiological, chemical analytical and data-analysis. During his PhD he pioneered the use of exhaled breath analysis in lung cancer, asthma and colorectal cancer amongst others. For this work he received various awards including a Marie Curie Fellowship.
Hamilton Scanlon joins as VP Manufacturing with over 30 years’ experience of taking products through the full development life cycle and into full scale production launch. His manufacturing experience ranges from start-up companies through to PLCs and he has been responsible for setting up manufacturing facilities within, China, Italy and the UK. Hamilton takes responsibility for manufacturing scale-up of Owlstone Medical’s clinical R&D tools used in biomarker discovery.
Commenting on the announcement, Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Owlstone Medical was created very specifically to advance our breathalyzer for very early stage diagnosis of disease when it can be treated more effectively for better patient outcomes. We are excited to see the company expanding so soon after being spun-out, and are confident that Chris, Marc and Hamilton will be great assets to the team.”
Dr Mike Cox and Jon Charters also join the Owlstone Medical team; Mike as Program Manager with responsibility for developing medical grade hardware used in diagnostic tests and supporting regulatory affairs; and Jon as QA/RA Manager focusing on the introduction of ISO 13485:2016 and FDA 21 CFR 820.
To find out more about Owlstone Medical visit: www.owlstonemedical.com
For more information:
Last updated on: 27/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.